Paul Aisen, MD, Director of the ADCS, expands on the significance of the ADCS DAPC independent analysis of the semagacestat trial which was published last week in the New England Journal of Medicine.
A team of scientists, including Paul Aisen, MD, professor of neuroscience and director of the Alzheimer’s Disease Cooperative Study, issued a sort of post-mortem on semagacestat, a small-molecule gamma-secretase inhibitor that drug developer Eli Lilly hoped would prove to be an effective treatment for Alzheimer’s disease (AD).